RDW Above 13% and All-Cause Mortality Risk
An RDW above 13% does indicate increased risk of all-cause mortality, with the threshold of clinical significance typically around 13.5-14.0% depending on the population studied.
Understanding RDW as a Prognostic Marker
RDW measures the variation in red blood cell size and is readily available from standard complete blood counts. While traditionally used to help diagnose iron deficiency anemia (where RDW >14.0% combined with low MCV suggests iron deficiency rather than thalassemia) 1, emerging evidence demonstrates RDW is a powerful independent predictor of mortality across multiple clinical contexts 2, 3, 4, 5.
Evidence for Mortality Risk
The most recent and highest quality evidence comes from a 2026 propensity-matched cohort study of 84,811 acute myocardial infarction patients, which found:
- RDW ≥13.5% was associated with 77% increased 1-year mortality risk (HR 1.77,95% CI 1.62-1.93) 2
- This association persisted even in non-anemic patients (HR 1.67,95% CI 1.50-1.85) 2
- Higher RDW also predicted major adverse cardiovascular events, heart failure, cardiogenic shock, and arrhythmias 2
Additional supporting evidence across different populations:
- In NSTEMI patients, RDW >13.4% independently predicted mortality (HR 3.008) with optimal cutoff at 13.4% 3
- In critically ill cardiovascular patients, RDW ≥15.0% showed 3.15-fold increased mortality risk, with graded increases starting at RDW 13.5-13.9% (OR 1.29) 4
- In unselected ICU patients, each 1% RDW increase raised 30-day mortality by 10%, 90-day by 11%, and 1-year by 13% 5
- In surgical patients, RDW ≥13.6% increased in-hospital mortality risk 2.65-fold, though this association was not seen in medical patients 6
Clinical Interpretation Algorithm
When evaluating RDW for mortality risk:
- RDW <13.0%: Normal range, baseline mortality risk
- RDW 13.0-13.4%: Borderline elevation, minimal increased risk
- RDW 13.5-13.9%: Mild elevation, 29% increased mortality risk 4
- RDW 14.0-14.4%: Moderate elevation, 57% increased mortality risk 4
- RDW ≥15.0%: Severe elevation, 215% increased mortality risk 4
Important Clinical Caveats
The RDW-mortality association is independent of anemia status 2. This is critical because clinicians often dismiss elevated RDW as simply reflecting anemia or iron deficiency. The prognostic value persists even when hemoglobin is normal.
RDW reflects underlying pathophysiology beyond iron status, including:
- Chronic inflammation and oxidative stress 7
- Ineffective erythropoiesis
- Nutritional deficiencies (iron, B12, folate) 8
- Bone marrow dysfunction
- Systemic illness severity
Context matters for threshold interpretation: The optimal cutoff varies by population—13.4% in NSTEMI 3, 13.5% in post-MI patients 2, 13.6% in surgical patients 6, and 14.0% in general populations 1. For practical risk stratification, use 13.5% as the threshold for concern in cardiovascular patients and 14.0% in general populations.
Diagnostic Workup When RDW is Elevated
When RDW is elevated, the minimum workup should include MCV, reticulocyte count, serum ferritin, transferrin saturation, and CRP to determine the underlying cause 8. However, even after identifying and treating the cause (e.g., iron deficiency), the elevated RDW itself signals increased mortality risk that warrants closer monitoring and more aggressive risk factor management.
In heart failure patients specifically, elevated RDW (>15.21%) showed 84% increased all-cause mortality risk 9, and in CHF with atrial fibrillation, RDW <16.565 showed particularly steep mortality increases 10.
The relationship between RDW and mortality is non-linear, with accelerating risk at higher values 4, 5, meaning patients with RDW >15% require particularly intensive monitoring and intervention.